Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

NCT04874194 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

24

Enrollment

OTHER

Sponsor class

Stopped The study terminated early because the company was longer providing the investigational product.

Conditions

Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Acute Biphenotypic Leukemia
Recurrent Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Biphenotypic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome

Interventions

DRUG: Omacetaxine Mepesuccinate
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center